Company News

NEWS  |  07.21.2022

CEll & Gene Day Image.jpg

Cell and Gene Therapy Industry Comes Together for Matica Bio’s New Global Event

Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, hosted an inaugural event this week, Global Cell & Gene Day, with CHA Medical & Bio Group, providing a specialized venue for learning, innovation and networking for the advancing cell and gene therapy market.

NEWS  |  05.03.2022

리본커팅.jpeg

Matica Bio Opens New Cell & Gene Therapy GMP Facility in Texas

Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the opening of its new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.

NEWS  |  03.30.2022

Pangyo Technovalley Site 2.jpg

CHA Medical & Bio Group Announces Groundbreaking for Its New Cell Gene Biobank Facility

CHA Medical & Bio Group officially began construction of its Cell Gene Biobank (CGB) facility in Pangyo, South Korea.  Investing over $250 million in the project, the new 710,000 ft2 site will comprise one of the world’s largest single facilities for cell and gene therapy manufacturing and advanced stem cell biobanking. The construction of the state-of-art facility is expected to be completed by the end of 2024.

NEWS  |  10.18.2021

Linkedin Image.gif

Matica Bio Announces Joint Research Agreement with Sartorius for the Development of Advanced Viral Vector Manufacturing Technology

Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on a number of studies together to streamline and optimize PAT technologies, automation software, and single-use platforms offered by Sartorius for large scale vector production.

NEWS  |  05.12.2021

Westinghouse Building (source).jpg

Photo provided by: Oldham Goodwin Group, LLC

Matica Biotechnology, Inc. Appoints Yun Jeong Song as new CEO

Matica Biotechnology, Inc. (Matica Bio) today announced that the Board of Directors has appointed Yun Jeong Song, MD, as the company's new Chief Executive Officer (CEO) to continue its expansion as a CDMO supporting the global cell and gene therapy industry. Dr. Song joined the company effective April 1st, 2021 after 3 years as CEO of ImmuneOncia Therapeutics, an international joint venture developing immuno-oncology therapies. Dr. Song succeeds Byung Se So, PhD, who will remain with Matica Bio as an advisor.

NEWS  |  03.08.2021

Fierce Pharma Logo.jpg

As viral vector demand surges, CDMO Matica establishes a beachhead in Texas

A lack of global capacity to produce cell and gene therapies has been exacerbated by an even more pressing need: to develop and manufacture coronavirus vaccines. So it appears the timing is right for Matica Biotechnology, a developer and producer of viral vectors, to put down roots in the United States.

The brand-new CDMO has teamed up with Texas A&M University and its advanced manufacturing center and started work on a 25,000 square-foot viral vector plant near the university's College Station campus.

NEWS  |  03.03.2021

collaboration logo (JPG) - website.jpg

Matica Biotechnology, Inc. Announces

Master Research Agreement with Texas A&M

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a master research agreement with the Center for Innovation in Advanced Development and Manufacturing (CIADM) at Texas A&M University Health Science Center (TAMHSC).  The agreement covers joint research and development projects for plasmid, protein and viral vector products in compliance with FDA regulations.

NEWS  |  02.23.2021

21005_0357.jpg

Matica Biotechnology, Inc. Announces

Groundbreaking for a New GMP Facility

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located in Providence Park at 2501 Earl Rudder Freeway in College Station.

 

NEWS  |  12.15.2020

AdobeStock_68923736.jpeg

Matica Biotechnology, Inc. Announces Plans to Construct GMP Facility for Viral Vector Production

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a lease agreement for the location of its GMP production facility located in College Station, TX. Construction of the 25,000 ft 2 facility will commence in Q4 2020 and is dedicated to the production of viral vectors used in cell and gene therapies, vaccines and oncolytic products. When completed, the facility will provide Matica Bio’s clients with comprehensive viral vector development, manufacturing and analytical services centrally located in one of the fastest-growing biotech regions in the United States.

CHA BIOTECH.jpg

NEWS  |  06.18.2020

CHA Biotech to Raise $62 mn to Bolster CDMO Business

CHA Biotech aims to raise a total of 75 billion won ($62 million) through issuances of bonds with option to equity swap to strengthen contract development and manufacturing servicing for global gene therapy developers, the Korean stem cell research company said in a regulatory filing on Wednesday.